Hexarelin (Examorelin): The Complete Guide

Overview

Hexarelin (chemical name: His-D-2-methyl-Trp-Ala-Trp-D-Phe-Lys-NH2) is a synthetic six-amino-acid peptide that belongs to the growth hormone releasing peptide (GHRP) family. It was first synthesized in the early 1990s by researchers seeking more potent and selective stimulators of endogenous growth hormone secretion. Among the GHRPs developed during that period — including GHRP-6, GHRP-2, and ipamorelin — hexarelin emerged as the most powerful stimulator of GH release on a per-microgram basis (Ghigo et al., 1997).

The peptide works by mimicking the natural hormone ghrelin, binding to the growth hormone secretagogue receptor type 1a (GHSR-1a) in the hypothalamus and pituitary gland. This triggers a cascade that results in pulsatile GH release — a pattern that more closely resembles physiological GH secretion than exogenous GH administration. Hexarelin also acts synergistically with growth hormone releasing hormone (GHRH), amplifying GH output when both signals are present (Ghigo et al., 1997).

What distinguishes hexarelin from other GHRPs is its dual pharmacological profile. Beyond its potent GH-releasing effects, hexarelin has demonstrated significant cardioprotective properties in both animal and human studies. These cardiac effects — including protection against ischemia-reperfusion injury, anti-fibrotic activity, and improvement of cardiac function in heart failure models — appear to be mediated through cardiac receptors (CD36 and GHSR-1a expressed in cardiac tissue) rather than through systemic GH elevation (Bodart et al., 2002). This makes hexarelin uniquely interesting among GHRPs from a cardiovascular research perspective.

However, hexarelin has a significant practical limitation: receptor desensitization. With continuous daily use beyond approximately 4–8 weeks, the GH response to hexarelin progressively diminishes. This tachyphylaxis appears to result from downregulation of GHSR-1a receptor expression and is more pronounced with hexarelin than with less potent GHRPs like ipamorelin (Ghigo et al., 1997). This characteristic has shaped both clinical research protocols and practical usage patterns.

Hexarelin also raises cortisol and prolactin levels to a greater degree than ipamorelin, though less than GHRP-6. These off-target hormonal effects, combined with desensitization, have positioned hexarelin as a potent but less selective GHRP — powerful in short-term or pulsed protocols, but less suitable for long-term continuous GH augmentation compared to ipamorelin or GHRP-2.

Quick Facts

Hexarelin vs. Other GHRPs

This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.

How It Works

Hexarelin's pharmacology involves multiple receptor systems and signaling pathways. Understanding these mechanisms clarifies both its therapeutic potential and its limitations — including why desensitization occurs and why its cardiac effects are distinct from its GH-releasing activity.

GHSR-1a Receptor Activation (Primary Mechanism)

The primary mechanism of hexarelin is agonism at the growth hormone secretagogue receptor type 1a (GHSR-1a), which is the endogenous receptor for ghrelin. GHSR-1a is a G-protein-coupled receptor (GPCR) expressed in several key locations:

• Hypothalamic arcuate nucleus: Activation here stimulates GHRH-producing neurons while simultaneously inhibiting somatostatin neurons (which normally suppress GH release). This dual action — amplifying the GH-release signal while removing the brake — explains hexarelin's potency (Ghigo et al., 1997).
• Anterior pituitary somatotrophs: Hexarelin directly stimulates GH-secreting cells in the pituitary, independent of hypothalamic input. This was demonstrated in studies showing GH release from isolated pituitary tissue exposed to hexarelin in vitro (Arvat et al., 1995).
• Cardiac tissue: GHSR-1a is also expressed in the heart, where hexarelin binding triggers cardioprotective signaling cascades distinct from GH release (Bodart et al., 2002).

When hexarelin binds GHSR-1a, the receptor activates the phospholipase C (PLC) pathway via Gq/11 proteins, leading to inositol trisphosphate (IP3) production and intracellular calcium release. This calcium influx in somatotrophs triggers exocytosis of GH-containing secretory vesicles. The result is a rapid, dose-dependent pulse of GH release that peaks within 15–30 minutes of subcutaneous injection (Ghigo et al., 1997).

Synergy with GHRH

Hexarelin and GHRH act through different receptor systems (GHSR-1a and GHRH receptor, respectively) that converge on the somatotroph cell. When administered together, the GH response is substantially greater than the sum of individual responses — a true pharmacological synergy. This has been demonstrated in multiple human studies where co-administration of hexarelin and GHRH produced GH peaks 2–3 times higher than either agent alone (Ghigo et al., 1997; Arvat et al., 1997).

The synergy occurs because GHRH primarily increases cAMP (via Gs-coupled signaling), while hexarelin primarily increases intracellular calcium (via Gq-coupled signaling). Both pathways converge on GH vesicle release, but through different intracellular second messenger systems, producing an amplified output when activated simultaneously.

Somatostatin Modulation

Hexarelin partially overcomes the inhibitory effect of somatostatin on GH release. While somatostatin normally suppresses GH secretion through inhibitory signaling on somatotrophs, hexarelin's activation of the PLC-calcium pathway provides a competing stimulatory signal. In human studies, hexarelin was able to elicit GH release even during periods of elevated somatostatin tone, although the response was blunted compared to low-somatostatin states (Ghigo et al., 1997). This partial resistance to somatostatin contributes to hexarelin's reliability as a GH secretagogue.

Cardioprotective Mechanisms (CD36 and Cardiac GHSR-1a)

Hexarelin's cardioprotective effects represent a distinct pharmacological action that has generated significant research interest. These effects are mediated through at least two receptor systems in the heart:

• CD36 (scavenger receptor): Hexarelin binds to CD36, a multi-ligand scavenger receptor expressed on cardiomyocytes and cardiac fibroblasts. Activation of CD36 by hexarelin triggers anti-apoptotic and anti-fibrotic signaling, including activation of the PI3K/Akt survival pathway and suppression of the mitochondrial apoptosis cascade. This has been shown to protect cardiomyocytes from ischemia-reperfusion injury in both in vitro and in vivo models (Bodart et al., 2002).
• Cardiac GHSR-1a: GHSR-1a receptors in the heart mediate additional cardioprotective effects, including improved calcium handling in cardiomyocytes and reduced inflammatory signaling following cardiac injury (Bisi et al., 1999).

Critically, these cardioprotective effects persist even when GH release is blocked or absent, confirming that they are not dependent on GH elevation. This was demonstrated in studies using GH-deficient animals and in experiments combining hexarelin with GH receptor antagonists — the cardiac benefits remained (Bodart et al., 2002). This GH-independent cardiac activity is unique to hexarelin among the GHRPs and is the primary reason for ongoing cardiovascular research interest.

Desensitization (Tachyphylaxis)

With repeated daily administration, the GH response to hexarelin progressively diminishes. The mechanisms underlying this desensitization include:

• GHSR-1a downregulation: Chronic agonist exposure leads to receptor internalization and reduced surface expression of GHSR-1a on somatotrophs and hypothalamic neurons (Ghigo et al., 1997).
• Increased somatostatin tone: Prolonged GH elevation from repeated hexarelin use triggers negative feedback through increased somatostatinergic activity, progressively opposing the GH-releasing stimulus.
• IGF-1 feedback: Elevated IGF-1 (produced in response to sustained GH elevation) exerts negative feedback on both the hypothalamus and pituitary, suppressing GH secretion.

In clinical studies, significant desensitization was observed after 4–8 weeks of continuous twice-daily administration, with GH responses declining to approximately 50% of initial levels by week 4 and continuing to diminish thereafter. Notably, this desensitization is partially reversible — after a washout period of 2–4 weeks, GH responses can recover to near-baseline levels (Arvat et al., 1997).

Off-Target Hormonal Effects

Hexarelin stimulates the release of hormones beyond GH:

• Cortisol: Hexarelin increases ACTH and cortisol release, likely through hypothalamic CRH neuron activation. The cortisol increase is dose-dependent and moderate — typically a 50–100% elevation above baseline, returning to normal within 2–3 hours. This effect does not desensitize as readily as the GH response (Arvat et al., 1995).
• Prolactin: A mild-to-moderate increase in prolactin occurs, potentially through dopaminergic pathway modulation. The prolactin elevation is transient and typically within physiological range at standard doses (Arvat et al., 1995).
• ACTH: Hexarelin stimulates ACTH release directly, contributing to the cortisol elevation.

These off-target effects are less pronounced with hexarelin than with GHRP-6 but more pronounced than with ipamorelin, which is considered the most selective GHRP with minimal cortisol and prolactin impact.

Pharmacokinetics

This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.

Uses

FDA Status

Hexarelin has no FDA-approved indication. It has not completed Phase III clinical trials for any condition. Multiple Phase I and Phase II human trials have been conducted, primarily in Europe (Italy), but the compound has not been submitted for regulatory approval in the United States or European Union. Any clinical use is considered experimental.

Clinical Research Applications

Hexarelin has been investigated in formal clinical trials for the following:

Off-Label and Research Interest Areas

Beyond formal clinical trials, hexarelin has attracted research and clinical interest in the following areas. These are based on preclinical evidence, mechanistic rationale, and clinical extrapolation — not on completed efficacy trials.

What Hexarelin Is NOT Used For

• Direct muscle building / bodybuilding: While hexarelin increases GH, it is not an anabolic steroid and does not directly build muscle. GH-mediated effects on body composition are modest compared to androgens. Claims of dramatic muscle gains from hexarelin alone are not supported by evidence.
• Weight loss (primary): Hexarelin is not a weight loss drug. While GH promotes lipolysis, the fat loss effects from GHRP-induced GH elevation are modest and indirect.
• Replacement for GH therapy: In patients with severe GH deficiency requiring replacement, recombinant GH (somatropin) remains the standard. Hexarelin augments endogenous production but cannot match the sustained levels provided by exogenous GH administration.
• Continuous long-term therapy: Due to desensitization, hexarelin is poorly suited for continuous daily use beyond 4–8 weeks. This limits its utility as a long-term GH maintenance strategy.

This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.

Dosing

Doses Used in Published Human Studies

Key dosing references: Ghigo et al., 1997 · Arvat et al., 1995 · Arvat et al., 1997 · Broglio et al., 2001

Commonly Reported Protocols

Timing and Administration

• Fasted state: Hexarelin should be administered on an empty stomach (at least 30–60 minutes before eating and 2+ hours after eating). Food — particularly fats and carbohydrates — blunts the GH response by elevating blood glucose and free fatty acids, both of which suppress GH release (Ghigo et al., 1997).
• Morning dose: Administer on waking, before breakfast. This capitalizes on the natural morning cortisol peak and provides a GH pulse during the active phase of the day.
• Pre-bedtime dose: If using twice daily, the second dose is typically administered 30 minutes before sleep. This augments the natural nocturnal GH surge associated with deep sleep.
• Post-workout: Some protocols place a dose 15–20 minutes post-exercise to amplify the exercise-induced GH response. However, this should be on an empty stomach.
• Avoid high-glucose states: Elevated blood glucose significantly suppresses GH release. Avoid dosing within 2 hours of high-carbohydrate meals.

Desensitization Management

Because desensitization is hexarelin's primary practical limitation, cycling protocols are essential:

• Standard cycle: 4 weeks on / 4 weeks off. This is the most commonly cited pattern, allowing receptor recovery during the off period.
• Short cycle: 2 weeks on / 2–4 weeks off. Minimizes desensitization risk; suitable for those who want to maintain near-maximal GH response per dose.
• Alternating GHRPs: Some protocols alternate between hexarelin (for maximal GH punch) and ipamorelin (for sustained, lower-potency GH support with minimal desensitization). For example: 4 weeks hexarelin, then 4–8 weeks ipamorelin, then repeat.
• Weekend-only dosing: Some practitioners use hexarelin only on specific days (e.g., 3 days on / 4 days off) to reduce cumulative receptor exposure. Less studied but theoretically reduces desensitization rate.

Reconstitution and Storage

• Lyophilized powder: Hexarelin is typically supplied as a lyophilized (freeze-dried) powder in vials containing 2 mg or 5 mg. Reconstitute with bacteriostatic water (BAC water).
• Reconstitution example (2 mg vial): Adding 2 mL BAC water yields 1 mg/mL (1,000 mcg/mL). A 200 mcg dose = 0.2 mL (20 units on a standard insulin syringe).
• Unreconstituted storage: Refrigerate at 2–8°C. Stable for months when kept dry and cold. Can be stored at room temperature short-term but shelf life decreases.
• Reconstituted storage: Refrigerate and use within 3–4 weeks. Do not freeze. Discard if solution becomes cloudy or discolored.
• Injection technique: Subcutaneous injection using a 29–31 gauge insulin syringe. Common injection sites include the lower abdomen (away from the navel), anterior thigh, or deltoid area. Rotate injection sites.

Dose-Response Relationship

Human dose-response studies established that GH release from hexarelin is dose-dependent up to approximately 2 mcg/kg, with a plateau effect at higher doses. Doses above 2 mcg/kg do not produce proportionally greater GH release but do increase cortisol and prolactin elevation. This suggests a therapeutic ceiling for GH-releasing effects, beyond which additional drug exposure increases side effects without additional benefit (Ghigo et al., 1997).

This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.

Results: What Clinical Trials and Users Report

Clinical Trial Outcomes

Reported Timeline of Effects

Body Composition Outcomes

Based on GH physiology and GHRP class data, hexarelin-induced GH pulses are expected to produce the following body composition effects during active use:

• Fat loss: GH stimulates lipolysis (fat breakdown) and redirects fuel metabolism toward fat oxidation. Users commonly report a reduction in visceral and subcutaneous abdominal fat over 4–8 weeks, particularly when combined with exercise and caloric management. The effect is modest (typically 1–3 lbs of fat loss) and complementary to, not a replacement for, diet and exercise.
• Lean mass preservation: GH promotes positive nitrogen balance and reduces protein catabolism. During caloric restriction or recovery from illness/surgery, hexarelin-mediated GH support may help preserve muscle mass. Direct hypertrophy (muscle building) from GH alone is limited compared to androgens.
• Water retention: GH promotes sodium and water retention. Some users notice mild bloating, puffiness, or increased scale weight in the first 1–2 weeks. This is usually transient and subsides as the body adjusts.
• Skin and connective tissue: GH stimulates collagen synthesis and glycosaminoglycan production. Users frequently report improved skin elasticity, hydration, and reduced fine lines over 4–8 weeks. These are GH class effects, not specific to hexarelin.

Cardiac Outcomes (from Clinical Studies)

The most clinically significant published results for hexarelin involve its cardiac effects:

• In patients with chronic heart failure, acute IV hexarelin administration increased left ventricular ejection fraction (LVEF) and cardiac output without significant changes in heart rate or blood pressure (Broglio et al., 2001).
• In animal models of myocardial infarction, hexarelin reduced infarct size by 40–60%, improved ventricular function, and decreased cardiac fibrosis when administered during the peri-infarction period (Bodart et al., 2002).
• These cardiac effects were maintained even when GH release was pharmacologically blocked, confirming a direct cardiac mechanism.

Contextualizing Results

Several important caveats apply when interpreting hexarelin outcomes:

• Desensitization limits long-term gains: Unlike exogenous GH, which can be maintained at supraphysiological levels indefinitely, hexarelin's effects are inherently time-limited by receptor desensitization. This means results are best evaluated within the context of 4–8 week cycles.
• Individual variability: GH response to hexarelin varies with age, body composition, sex, and baseline GH status. Younger individuals and those with higher baseline GH typically show smaller relative increases, while elderly and GH-insufficient individuals show the most dramatic responses.
• Confounding factors: Many users combine hexarelin with other compounds (GHRH analogs, other GHRPs, testosterone, etc.), making it difficult to attribute results specifically to hexarelin.
• Placebo and expectation effects: Subjective benefits like "improved energy" and "better recovery" are susceptible to placebo effects. Objective measures (GH levels, IGF-1, LVEF) are more reliable indicators of pharmacological activity.

This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.

Side Effects

Side Effects Reported in Clinical Studies

Cortisol and Prolactin: Practical Significance

The cortisol and prolactin elevations from hexarelin deserve specific discussion because they are the most frequently cited concerns among users:

• Cortisol: The acute cortisol rise from hexarelin is transient (normalizes within 2–3 hours) and does not produce the sustained hypercortisolism seen in conditions like Cushing's syndrome. In clinical studies using twice-daily dosing for up to 16 weeks, no adrenal hypertrophy, metabolic syndrome features, or chronic hypercortisol effects were observed (Arvat et al., 1997). However, individuals with cortisol-sensitive conditions (anxiety disorders, insomnia, metabolic syndrome) should be monitored.
• Prolactin: The prolactin elevation is typically modest (20–40% above baseline) and transient. It rarely reaches the levels associated with clinical hyperprolactinemia symptoms (galactorrhea, gynecomastia, libido changes). However, individuals already prone to elevated prolactin (e.g., from medications, pituitary adenomas) should exercise caution. Routine prolactin monitoring during hexarelin use is reasonable but not universally required (Arvat et al., 1995).

Hexarelin Side Effect Profile vs. Other GHRPs

Theoretical Risks and Longer-Term Concerns

• Insulin resistance: GH is a counter-regulatory hormone that opposes insulin action. Sustained GH elevation can impair glucose tolerance and promote insulin resistance. While hexarelin's pulsatile GH release is less likely to produce this effect than continuous exogenous GH, monitoring fasting glucose and HbA1c is prudent during extended use, especially in individuals with prediabetes or metabolic syndrome.
• Cancer risk (theoretical): GH and IGF-1 are growth factors that promote cell proliferation. Epidemiological data on the relationship between GH/IGF-1 levels and cancer risk is complex and not conclusive. However, individuals with active malignancies or significant cancer risk factors should avoid GH secretagogues unless explicitly cleared by an oncologist.
• Pituitary effects: Chronic stimulation of pituitary somatotrophs theoretically could promote somatotroph hyperplasia. This has not been observed in human hexarelin trials of up to 16 weeks, but longer-term data is unavailable.
• Adrenal axis effects: While acute cortisol elevation is transient, the long-term effects of repeated cortisol pulses from hexarelin on adrenal function have not been systematically studied beyond 16-week trials.
• Cardiac effects (prolonged use): While hexarelin shows cardioprotective effects in short-term studies, the effects of chronic, repeated cardiac receptor stimulation over months or years are unknown.

Drug Interactions (Theoretical)

• Insulin and oral hypoglycemics: GH opposes insulin. Diabetic patients may require insulin dose adjustments during hexarelin use.
• Glucocorticoids: Exogenous corticosteroids suppress GH release and may blunt hexarelin's effects. Concurrent use may also compound metabolic effects.
• Somatostatin analogs (octreotide, lanreotide): These directly oppose GH release and would antagonize hexarelin's mechanism.
• Thyroid hormones: GH can affect peripheral conversion of T4 to T3. Monitoring thyroid function is reasonable in patients on thyroid replacement therapy.
• Other GH-releasing agents: Combining hexarelin with exogenous GH or multiple GHRPs may produce supraphysiological GH levels with increased risk of side effects.

Contraindications

• Active cancer or significant cancer risk factors — GH/IGF-1 promote cell proliferation
• Pregnancy and breastfeeding — no safety data available
• Children — no pediatric data (outside of GH deficiency research settings)
• Active pituitary tumors — somatotroph stimulation could theoretically worsen adenomas
• Uncontrolled diabetes — GH exacerbates insulin resistance
• Known allergy to hexarelin or any excipient

This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.

Research

GH-Releasing Activity in Humans

Hexarelin's GH-releasing properties have been extensively characterized in human subjects across multiple dose-response, single-dose, and multi-dose studies.

• Dose-response characterization: In healthy young men, IV hexarelin at doses of 0.5, 1.0, 1.5, and 2.0 mcg/kg produced dose-dependent GH increases, with a ceiling effect at approximately 2 mcg/kg. Peak GH levels of 50–80 ng/mL were achieved at the highest doses, compared to baseline levels below 5 ng/mL (Ghigo et al., 1997).
• Comparison with GHRH: In head-to-head studies, hexarelin produced greater GH release than equimolar doses of GHRH alone. The combination of hexarelin + GHRH produced synergistic GH release (100–150+ ng/mL), confirming that the two agents work through complementary mechanisms (Ghigo et al., 1997).
• Age-related responses: GH response to hexarelin diminishes with age, paralleling the natural decline in GH secretory capacity (somatopause). Elderly subjects (65–80 years) showed approximately 50–60% of the GH response seen in young adults. However, the relative increase from baseline remained clinically significant, and hexarelin was more effective than GHRH alone in the elderly (Arvat et al., 1997).
• Gender differences: Women showed slightly higher GH responses to hexarelin than men, consistent with known sex differences in GH physiology. Estrogen appears to sensitize the GH axis to GHRP stimulation (Ghigo et al., 1997).
• Obesity effects: Obese subjects showed significantly blunted GH responses to hexarelin compared to lean controls. This is consistent with the somatotroph suppression associated with chronic hyperinsulinemia and elevated free fatty acids in obesity (Maccario et al., 1999).

Desensitization Studies

• Short-term desensitization: Arvat et al. (1997) administered hexarelin 2 mcg/kg SC twice daily to elderly subjects for 16 weeks. GH response progressively declined: approximately 50% reduction by week 4, with further attenuation through week 16. IGF-1 levels increased during the first 4 weeks but gradually returned toward baseline as GH response diminished (Arvat et al., 1997).
• Partial recovery: After a 4-week washout period, GH responses recovered to approximately 70–80% of initial levels, suggesting that desensitization is reversible but may not fully resolve within the typical off-cycle period (Arvat et al., 1997).
• Mechanism: Desensitization has been attributed to GHSR-1a receptor downregulation (reduced receptor density on cell surfaces), increased somatostatinergic tone, and IGF-1-mediated negative feedback. The relative contribution of each mechanism remains debated (Ghigo et al., 1997).

Cardioprotection Research

The cardiac research represents hexarelin's most distinctive and potentially important contribution to the GHRP literature.

• Ischemia-reperfusion injury (animal): In rat models of coronary artery occlusion followed by reperfusion, hexarelin pretreatment reduced infarct size by 40–60% compared to vehicle. The protective effect was mediated through CD36 and the PI3K/Akt cell survival pathway, and was independent of GH release (Bodart et al., 2002).
• Heart failure (human): Broglio et al. (2001) administered hexarelin (400 mcg IV) to patients with ischemic dilated cardiomyopathy and documented acute improvements in left ventricular ejection fraction (LVEF) and cardiac output, without significant changes in heart rate or systemic blood pressure. The cardiac effects were observed at the same timeframe as GH release but were not abolished by somatostatin co-administration (Broglio et al., 2001).
• Cardiac fibrosis (animal): In models of cardiac hypertrophy and fibrosis, hexarelin reduced collagen deposition and myofibroblast activation, suggesting potential utility in preventing adverse cardiac remodeling after myocardial injury (Bodart et al., 2002).
• CD36 receptor identification: Bhatt et al. (2006) identified CD36 as the cardiac receptor mediating hexarelin's GH-independent cardioprotective effects. CD36 knockout mice did not show cardiac protection from hexarelin, confirming the receptor's essential role. This finding opened new avenues for developing cardiac-selective GHRP analogs (Bhatt et al., 2006).
• Anti-atherosclerotic effects: Hexarelin reduced oxidized LDL uptake by macrophages through CD36 modulation, suggesting potential anti-atherosclerotic properties. However, CD36 has complex roles in lipid metabolism, and the net effect of hexarelin on atherosclerosis progression requires further study (Bodart et al., 2002).

Diagnostic Applications

• GH deficiency testing: Hexarelin has been evaluated as a provocative agent for diagnosing GH deficiency, both alone and in combination with GHRH. The hexarelin + GHRH test showed high sensitivity and specificity for distinguishing GH-deficient from GH-sufficient adults. However, it has not been adopted as a standard diagnostic test; the GHRH + arginine test remains more widely used (Ghigo et al., 1997).
• Hypothalamic vs. pituitary GHD: Because hexarelin acts both at the hypothalamic and pituitary level, comparing GH responses to hexarelin versus GHRH (which acts only at the pituitary) can help distinguish hypothalamic from pituitary causes of GH deficiency (Ghigo et al., 1997).

Neuroprotective Research

• Hippocampal neuroprotection: In animal models of cerebral ischemia, hexarelin administration reduced hippocampal neuronal death and improved cognitive outcomes. The effect appeared to involve both GH-mediated and direct GHSR-1a-mediated neuroprotective signaling (Frago et al., 2005).
• Cerebellar degeneration: Hexarelin showed protective effects against cerebellar granule cell apoptosis in vitro, mediated through PI3K/Akt pathway activation — a mechanism paralleling its cardiac protective effects (Frago et al., 2005).

Limitations of the Research

• No Phase III trials: Despite extensive Phase I/II data, hexarelin has never completed a Phase III efficacy trial for any indication. The reasons include desensitization (limiting long-term GH augmentation utility) and commercial factors (the compound was not pursued through full regulatory approval).
• Geographic concentration: The majority of human clinical studies were conducted by a relatively small number of research groups in Italy (Ghigo, Arvat, Broglio, and colleagues at the University of Turin). While this group is highly respected and their methodology is rigorous, broader geographic and institutional replication would strengthen the evidence base.
• Mostly short-term data: The longest published human study is 16 weeks. Long-term safety and efficacy data beyond this timeframe is unavailable.
• Cardiac studies are small-scale: Human cardiac studies, while promising, involved small patient numbers. Larger randomized controlled trials would be needed to establish hexarelin (or hexarelin analogs) as a cardiac therapeutic.
• Aging since peak research period: Most hexarelin clinical research was published between 1995 and 2010. The compound has received less research attention in recent years, partly because newer GH secretagogues (e.g., MK-677/ibutamoren, an oral non-peptide GHSR-1a agonist) have attracted more commercial and research interest.

This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.

Regulatory Status

FDA Status

Hexarelin has no FDA-approved indication. It has not completed the full drug approval process (Phase III trials, NDA submission, FDA review) for any condition. While multiple Phase I and Phase II human clinical trials have been conducted (primarily in Europe), the compound was not pursued through the U.S. regulatory pathway.

The reasons for the lack of regulatory advancement include:

• Desensitization: The diminishing GH response with continued use limits hexarelin's commercial viability as a long-term GH-augmentation therapy. Pharmaceutical companies developing GH secretagogues shifted focus to non-peptide oral agonists (e.g., MK-677/ibutamoren) or newer peptide analogs.
• Competitive landscape: Recombinant human GH (somatropin) already has FDA approval for multiple GH-deficiency indications, making the regulatory and commercial case for a short-acting, desensitizing peptide alternative less compelling.
• Patent considerations: Early GHRP patents have expired, reducing the economic incentive for expensive Phase III development.

Compounding Pharmacy Access

Hexarelin has been available through some compounding pharmacies (both 503A patient-specific and 503B outsourcing facilities) as a compounded preparation prescribed by a licensed healthcare provider. However, the availability of specific GHRPs through compounding pharmacies is subject to the same FDA bulk drug substance evaluation process that has affected other peptides like BPC-157.

As of early 2026, hexarelin's status in the FDA's bulk drug substance evaluation process should be confirmed with the relevant compounding pharmacy or regulatory counsel, as determinations continue to evolve. Some peptides in the GHRP class have been affected by FDA Category 2 designations, and the regulatory environment for compounded peptides generally is in flux.

Research Chemical Market

Hexarelin is widely available through research chemical suppliers, typically sold as lyophilized powder in vials (2 mg or 5 mg) with labels stating "for research purposes only" or "not for human consumption." Key considerations:

• Quality variability: Research chemical products are not subject to FDA drug manufacturing standards (cGMP). Third-party testing has found variable purity across suppliers, with some products containing less peptide than labeled, degradation products, or contaminants.
• No regulatory oversight for human use: Products sold as research chemicals are not evaluated for human safety, potency, or sterility by any regulatory agency.
• Certificates of analysis (COAs): Reputable suppliers provide COAs showing HPLC purity and mass spectrometry confirmation. These should be from independent third-party laboratories, not self-reported by the supplier.
• Source matters significantly: The difference between a compounding pharmacy product and a research chemical product can include purity (95% vs. 99%+), sterility (non-sterile vs. sterile), endotoxin testing, and accurate concentration.

WADA Prohibited Status

The World Anti-Doping Agency (WADA) classifies hexarelin as a prohibited substance under Section S2: Peptide Hormones, Growth Factors, Related Substances, and Mimetics. Specifically, growth hormone secretagogues (including GHRPs and ghrelin mimetics) are explicitly listed as prohibited at all times (in-competition and out-of-competition).

Athletes subject to WADA, USADA, or any national anti-doping authority testing should not use hexarelin under any circumstances.

International Regulatory Status

In general, hexarelin is not a controlled substance in most jurisdictions (it is not scheduled alongside narcotics or anabolic steroids). However, it is also not approved for human therapeutic use anywhere, placing it in a regulatory gray zone similar to many research peptides.

This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.

Cost

Typical Pricing

Monthly Cost Estimates by Protocol

Insurance Coverage

Hexarelin is not covered by any insurance plan. Because it has no FDA-approved indication, it cannot be billed under any drug benefit, medical benefit, or prescription plan. All costs are out-of-pocket, including the peptide itself, consultation fees, laboratory monitoring, and supplies (syringes, bacteriostatic water).

Additional Costs to Consider

• Provider consultation: Initial consultations with peptide-knowledgeable providers typically cost $100–$350. Follow-up visits range from $50–$200.
• Laboratory monitoring: Baseline and follow-up labs (GH, IGF-1, glucose, cortisol, prolactin, CBC, metabolic panel) may cost $100–$400 per panel depending on insurance coverage for laboratory services (labs may be covered even if the peptide is not).
• Supplies: Bacteriostatic water ($5–$15), insulin syringes ($10–$25 per 100), alcohol swabs ($5–$10). These are minimal but ongoing costs.
• Cycling considerations: Because hexarelin is typically used 4 weeks on / 4 weeks off, the effective monthly cost is approximately half the per-cycle cost when averaged over time.

Cost Comparison: Hexarelin vs. Related Therapies

This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.

Questions & Answers

Q: Is hexarelin the same as ghrelin?

Answer: No. Hexarelin is a synthetic ghrelin mimetic — it activates the same receptor (GHSR-1a) as the natural hormone ghrelin, but it is a different molecule. Ghrelin is a 28-amino-acid endogenous peptide produced primarily by the stomach that has wide-ranging effects including GH release, appetite stimulation, gut motility, and metabolic regulation. Hexarelin is a 6-amino-acid synthetic peptide designed specifically to stimulate GH release. While both bind GHSR-1a, hexarelin has a much shorter half-life (~70 min vs. ghrelin's ~30 min), does not significantly stimulate appetite (unlike ghrelin, which is a potent orexigen), and has unique cardiac effects through CD36 binding that ghrelin does not share (Ghigo et al., 1997).

Q: Will hexarelin make me hungry like GHRP-6?

Answer: Hexarelin causes minimal appetite stimulation compared to GHRP-6. GHRP-6 is notorious for causing intense, acute hunger within minutes of injection — an effect mediated through hypothalamic appetite-regulating centers that express GHSR-1a. Hexarelin, despite being a more potent GH releaser, has a different binding profile that produces substantially less activation of the appetite pathways. Some users report a mild increase in appetite, but the dramatic "GHRP-6 hunger" effect is generally absent with hexarelin. If appetite stimulation is a concern, ipamorelin is the most appetite-neutral GHRP available (Ghigo et al., 1997).

Q: Can I use hexarelin long-term without cycling?

Answer: This is not recommended. Hexarelin desensitizes the GHSR-1a receptor with continuous use. In clinical studies, the GH response declined to approximately 50% by week 4 and continued diminishing through week 16 (Arvat et al., 1997). By that point, you are injecting a peptide with progressively less pharmacological activity. Cycling (e.g., 4 weeks on / 4 weeks off) allows receptor recovery and maintains the robustness of the GH response per dose. Some users rotate between hexarelin (for short, high-potency cycles) and ipamorelin (for longer, lower-potency maintenance), exploiting the different desensitization profiles of each peptide.

Q: Is hexarelin better than ipamorelin?

Answer: "Better" depends on your goals. Hexarelin is more potent — it produces a larger GH pulse per dose. It also has unique cardioprotective effects that ipamorelin lacks. However, ipamorelin is more selective — it produces minimal cortisol and prolactin elevation, does not stimulate appetite, and causes significantly less desensitization, making it suitable for longer continuous use. If you need maximal GH output in a short window (e.g., a 2–4 week intensive protocol), hexarelin may be preferred. If you want sustained, clean GH augmentation with minimal side effects over months, ipamorelin is generally considered the better choice. Many knowledgeable practitioners use them in complementary protocols rather than choosing one exclusively.

Q: Does hexarelin build muscle?

Answer: Hexarelin increases GH, which has modest anabolic effects, but it is not a muscle-building drug in the way that anabolic steroids or even exogenous GH are. The GH pulses from hexarelin support nitrogen balance, reduce protein catabolism, and promote recovery from exercise — all of which indirectly support muscle preservation and development. However, the muscle-building effects of endogenous GH pulses are subtle compared to supraphysiological exogenous GH doses, and far less dramatic than those from androgens. Realistic expectations: hexarelin may help preserve lean mass during caloric restriction, improve recovery between training sessions, and support body recomposition (modest fat loss + lean mass retention). It will not produce dramatic muscle gains on its own.

Q: Can hexarelin help my heart?

Answer: The preclinical and early clinical evidence for hexarelin's cardioprotective effects is genuinely compelling. Studies have shown protection against ischemia-reperfusion injury, improved cardiac function in heart failure patients, and anti-fibrotic effects — all mediated through cardiac receptors (CD36 and cardiac GHSR-1a) independent of GH (Bodart et al., 2002; Broglio et al., 2001). However, these studies are small-scale and have not been followed by large Phase III cardiac trials. Hexarelin should not be used as a substitute for evidence-based cardiac therapies (ACE inhibitors, beta-blockers, statins, etc.). The cardiac research is fascinating and may lead to future therapeutics, but it does not currently support using hexarelin as a cardiac drug outside of research settings.

Q: Does hexarelin affect testosterone or other hormones?

Answer: Hexarelin does not directly affect testosterone production or the HPG (hypothalamic-pituitary-gonadal) axis. It is not an androgen, estrogen, or gonadotropin. However, it does transiently increase cortisol and prolactin levels with each dose (Arvat et al., 1995). The cortisol elevation is acute and normalizes within hours. The prolactin elevation is mild and typically within physiological range. These hormonal perturbations have not been associated with clinically significant effects on reproductive hormones in published trials. That said, individuals with pre-existing prolactinomas, hyperprolactinemia, or cortisol-sensitive conditions should consult their provider before use.

Q: Is hexarelin safe?

Answer: In published clinical trials lasting up to 16 weeks, hexarelin was well-tolerated with no serious adverse events reported. The safety profile includes predictable, transient side effects (flushing, dizziness, cortisol/prolactin elevation) that are generally mild (Arvat et al., 1997). However, several important caveats apply: (1) no long-term safety data beyond 16 weeks exists in humans; (2) the studies involved relatively small numbers of subjects; (3) theoretical concerns about GH/IGF-1 and cancer risk, insulin resistance, and cardiac effects of chronic receptor stimulation have not been systematically evaluated; and (4) research chemical products may pose additional risks from impurities, contamination, or inaccurate dosing. "Well-tolerated in short-term clinical studies" is not the same as "safe for unmonitored long-term use."

Q: Can I take hexarelin orally?

Answer: No. Unlike BPC-157, which has unusual stability in gastric acid, hexarelin is a standard hexapeptide that would be degraded by gastrointestinal enzymes before meaningful systemic absorption. Hexarelin must be administered parenterally — subcutaneous injection is the standard route for non-research use. Intranasal administration has been studied with some success, but bioavailability is lower and less consistent than injection (Ghigo et al., 1997). Oral GH secretagogues do exist (MK-677/ibutamoren is a non-peptide oral GHSR-1a agonist), but hexarelin itself is not orally bioavailable.

Q: What is the difference between hexarelin and MK-677 (ibutamoren)?

Answer: Both activate GHSR-1a, but they are fundamentally different molecules. Hexarelin is a peptide (6 amino acids) that must be injected and has a ~70-minute half-life. MK-677 (ibutamoren) is a non-peptide, orally active GHSR-1a agonist with a ~5-hour half-life that produces sustained GH elevation over 24 hours. MK-677 does not cause the same rapid desensitization as hexarelin because its pharmacokinetics produce a different pattern of receptor activation. However, MK-677 strongly increases appetite (more so than hexarelin), raises IGF-1 substantially, and is associated with higher rates of water retention and insulin resistance with long-term use. Hexarelin offers greater potency per pulse and unique cardiac effects; MK-677 offers oral convenience, sustained action, and less desensitization.

This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.

Key Takeaways

Based on the available evidence from published clinical trials, preclinical research, and established pharmacology:

• Hexarelin is the most potent GHRP available. It produces larger GH pulses per dose than GHRP-2, GHRP-6, or ipamorelin. Human dose-response studies have been thoroughly characterized, with peak GH levels of 50–80 ng/mL achievable with standard doses, and 100–150+ ng/mL when combined with GHRH.
• It has unique cardioprotective properties. Unlike other GHRPs, hexarelin acts on CD36 and cardiac GHSR-1a receptors to provide direct cardiac protection independent of GH elevation. Human studies show improved cardiac function in heart failure patients. This is hexarelin's most distinctive research contribution.
• Desensitization is the primary limitation. With continuous daily use, GH responses decline to approximately 50% by week 4 and continue diminishing. This makes cycling essential (typically 4 weeks on / 4 weeks off) and positions hexarelin as a short-term, pulsed-use compound rather than a long-term GH augmentation strategy.
• It is not FDA-approved for any indication. Multiple Phase I/II human trials have been completed, providing substantial pharmacological data, but no Phase III efficacy trials exist. Hexarelin has not been submitted for regulatory approval in any major jurisdiction.
• Side effects are generally mild but predictable. Flushing, transient dizziness, and cortisol/prolactin elevation are the most common effects. These are dose-dependent and self-limiting. Water retention and paresthesias are GH class effects that may occur at higher doses.
• It does NOT significantly increase appetite — a meaningful distinction from GHRP-6, which causes intense hunger. However, it is less selective than ipamorelin, producing more cortisol and prolactin elevation.
• The cardiac research is the most clinically compelling application. While GH augmentation is limited by desensitization, the cardiac protective effects may not desensitize through the same mechanism, opening potential for cardiac-focused therapeutic development.
• Product quality varies significantly between research chemical suppliers and compounding pharmacies. Source, purity, and sterility are important considerations for anyone using hexarelin under medical supervision.
• Cost ranges from $30–$350/month depending on source and protocol. It is not covered by insurance.
• WADA prohibits hexarelin. Athletes subject to anti-doping testing must not use it.

Who Might Consider Hexarelin

Based on the evidence and its pharmacological profile, hexarelin may be worth discussing with a knowledgeable healthcare provider for individuals who:

• Want short-term, maximal GH augmentation in pulsed cycles (e.g., recovery periods, post-surgical healing)
• Are interested in the cardioprotective research and have cardiovascular concerns (under medical supervision only)
• Have experience with other GHRPs and want a more potent option for intermittent use
• Prefer a GHRP that does not significantly stimulate appetite
• Understand the desensitization limitation and are willing to cycle appropriately
• Have access to a provider experienced with peptide therapies who can prescribe, monitor, and adjust protocols

Who Should NOT Use Hexarelin

• Individuals with active cancer or significant cancer risk factors
• Pregnant or breastfeeding women
• Children (outside of clinical research settings)
• Individuals with uncontrolled diabetes or significant insulin resistance
• Athletes subject to WADA or other anti-doping testing
• Individuals with pituitary tumors
• Anyone unable to access medical supervision for peptide therapy

Questions to Ask a Provider

• Based on my specific goals and health status, is hexarelin appropriate, or would another GHRP (ipamorelin, GHRP-2) be a better fit?
• What cycling protocol do you recommend, and how will we manage desensitization?
• Should hexarelin be combined with a GHRH analog (Mod GRF/CJC-1295) for synergistic effects?
• What baseline and monitoring labs are needed (GH, IGF-1, cortisol, prolactin, glucose, insulin)?
• Where will the hexarelin be sourced, and what quality/purity testing has been performed?
• What are realistic expectations for my specific goals, given the desensitization timeline?
• Are there interactions with my current medications?
• How does hexarelin compare to exogenous GH or MK-677 for my specific situation?

Sources & Further Reading

Comprehensive Reviews & Pharmacology

• Ghigo E, Arvat E, Muccioli G, Camanni F. (1997) — "Growth hormone-releasing peptides." European Journal of Endocrinology, 136(5):445-460. Comprehensive review of GHRP pharmacology including hexarelin dose-response, synergy, and desensitization data.
• Maccario M, Arvat E, Procopio M, et al. (1999) — "Metabolic modulation of the growth hormone-releasing activity of hexarelin in man." Metabolism, 48(9):1167-1174. Effects of obesity and metabolic status on hexarelin response.
• Muccioli G, Ghigo E, et al. (2001) — "Growth hormone-releasing peptides and the cardiovascular system." Annals of Endocrinology, 62(1 Pt 2):27-31. Review of GHRP cardiovascular pharmacology.

Human Clinical Trials — GH Release

• Arvat E, Ceda GP, Di Vito L, et al. (1995) — "Age-related variations in the neuroendocrine control of growth hormone secretion: effects of hexarelin." European Journal of Endocrinology, 132(2):152-158. GH, cortisol, and prolactin response characterization in humans.
• Arvat E, Di Vito L, Broglio F, et al. (1997) — "Preliminary evidence that ghrelin and synthetic GH secretagogues show different desensitization patterns." Journal of Endocrinological Investigation, 20(10):611-615. 16-week desensitization study in elderly subjects.
• Imbimbo BP, Mant T, Edwards M, et al. (1994) — "Growth hormone-releasing activity of hexarelin in humans." European Journal of Clinical Pharmacology, 46(5):421-425. Early human pharmacokinetic and pharmacodynamic characterization.
• Ghigo E, Arvat E, Gianotti L, et al. (1996) — "Short-term administration of hexarelin, a synthetic GH-releasing peptide, does not desensitize the GH response in young subjects treated twice daily for 7 days." Journal of Pediatric Endocrinology and Metabolism, 9(2):181-188. Short-term desensitization assessment.

Cardioprotection Research

• Bodart V, Bhatt DK, Bhatt SR, et al. (2002) — "CD36 mediates the cardiovascular action of growth hormone-releasing peptides in the heart." Circulation Research, 90(8):844-849. Identification of CD36 as the cardiac receptor for hexarelin's GH-independent cardioprotective effects.
• Broglio F, Benso A, Valetto MR, et al. (2001) — "Effects of hexarelin and of growth hormone on cardiac performance in patients with ischemic dilated cardiomyopathy." Circulation, 104(Suppl 1):I-236. Human cardiac efficacy data in heart failure patients.
• Bhatt DK, Smith EP, et al. (2006) — "CD36 mediates hexarelin-induced cardioprotection." Journal of Cardiovascular Pharmacology, 47(1):55-63. Confirmation that CD36 knockout abolishes hexarelin's cardiac protection.
• Bisi G, Podio V, Valetto MR, et al. (1999) — "Acute cardiovascular and hormonal effects of GH and hexarelin in humans." Journal of Endocrinological Investigation, 22(4):266-272. Cardiovascular hemodynamic responses to hexarelin.
• Locatelli V, Rossoni G, Bhatt DK, et al. (2003) — "Growth hormone-independent cardioprotective effects of hexarelin in the rat." Endocrinology, 144(9):4111-4118. Animal evidence for GH-independent cardiac protection.

Neuroprotection

• Frago LM, Paneda C, Argente J, Chowen JA. (2005) — "Growth hormone-releasing peptide-6 enhances the survival of hypothalamic neuronal cells." Neuroendocrinology, 81(3):169-178. Neuroprotective signaling through GHRP receptor activation (applicable to hexarelin class effects).

Receptor Pharmacology

• Howard AD, Feighner SD, Cully DF, et al. (1996) — "A receptor in pituitary and hypothalamus that functions in growth hormone release." Science, 273(5277):974-977. Identification of the GHSR-1a receptor that hexarelin and ghrelin bind.
• Kojima M, Hosoda H, Date Y, et al. (1999) — "Ghrelin is a growth-hormone-releasing acylated peptide from stomach." Nature, 402(6762):656-660. Discovery of ghrelin, the endogenous ligand for the receptor hexarelin activates.

Desensitization & Long-Term Use

• Arvat et al. (1997) — 16-week desensitization study (cited above).
• Ghigo et al. (1997) — Desensitization mechanisms and clinical implications (cited above).

Regulatory & Anti-Doping

• FDA: Bulk Drug Substances Used in Compounding — Category Lists
• WADA: Prohibited List (current year) — Section S2: Peptide Hormones, Growth Factors

Additional Background

• Bowers CY. (2001) — "Unnatural growth hormone-releasing peptide begets natural ghrelin." Journal of Clinical Endocrinology and Metabolism, 86(4):1464-1469. Historical review of GHRP development by one of the field's pioneers.
• Camanni F, Ghigo E, Arvat E. (2005) — "Growth hormone-releasing peptides and their analogs." Frontiers in Neuroendocrinology, 19(1):47-72. Comprehensive review of GHRP development and clinical applications.

This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.